Imiquimod efficacious in melanoma in situ tumor reduction

Source: Healio, May 2023

Key takeaways:

  • Imiquimod treatment for 16 weeks exhibited a 90% tumor clearance rate in persistent MMIS at margins of resection.
  • Long-term treatment efficacy should be assessed in larger studies.

Patients with persistent melanoma in situ have shown tumor clearance with imiquimod after surgery, according to a study.

“In a select population who have maxed out surgical options and/or refuse further resection with persistent margin positive melanoma in situ, imiquimod appears to be useful,” Jonathan S. Zager, MD, FACS, chief academic officer, director of regional therapies, chair of the department of oncologic sciences and professor of surgery at University of South Florida Morsani School of Medicine, told Healio.